
    
      Subjects transitioned to this observational study immediately upon exit from the
      802-247-09-032 trial. This ensured a total of 12 months of safety observations and wound
      status data were obtained from the time of the first application of HP802-247. This study
      provided consecutive visits at intervals of 8 weeks until a total of 12 months of safety
      follow-up had been achieved, based on the initial application of Investigational Medicinal
      Product in the prior study. Specifically, this study examines all new and unresolved ongoing
      adverse events.
    
  